Pfizer's Sigvotatug Vedotin Fails Lung Cancer Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Pfizer said its experimental drug sigvotatug vedotin fell short in a clinical trial designed to test it as a replacement for docetaxel — a chemotherapy initially approved in 1996 — in one of the most common forms of lung cancer.
- Albert Bourla, Pfizer's CEO, said on an earnings call last year that sigvotatug vedotin "could be a driver of growth later this decade."
- Leerink analyst David Risinger called the upcoming data readout a "major oncology catalyst" in a May note to investors, and said he had spoken to a doctor who was "optimistic" about the drug's potential.
- Pfizer acquired sigvotatug vedotin through its $43 billion purchase of biotechnology firm Seagen in 2023.
Why it matters: Pfizer loses a key oncology candidate from its $43 billion Seagen acquisition — one CEO Albert Bourla had publicly called a potential growth driver — dashing hopes it could supplant the 1996-era chemotherapy docetaxel in a common lung cancer setting. Analyst and CEO enthusiasm that framed this drug as a "major oncology catalyst" now collides with a negative readout, raising the stakes on whether other Seagen assets can carry the deal's promised value.
